Quote:
Originally Posted by KWIL
May the research move ahead with as much speed as possible, finance should not be allowed to limit their work.
|
Hmmm, having spent 25 years producing Asthma/COPD/HIV drugs I can tell you the amount of finance going into the R&D is eye watering. The reason why there may be a dearth in new product introduction is that governments want drugs at knock-down prices but the pharma companies need to make big profits to plough ever increasing amounts into the research. The drug is often only patent protected for ten years and unless the drug is in vast volume production the company will not have covered R&D costs and thus not bother with the introduction.
Kev